IBI305 vs. Compounded Avastin – A Biosimilar Breakthrough for Safer and More Cost-Effective Retinal Therapies

Retinal diseases, such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), demand accessible and safe therapies. Off-label use of bevacizumab (Avastin®) in ophthalmology raises safety concerns due to compounding practices, including risks of endophthalmitis and dose inconsistencies. The FDA/EMA-approved biosimilar IBI305 addresses these limitations with a single-use vial formulation, eliminating contamination risks and ensuring manufacturing compliance. Clinical studies confirm its pharmacokinetic equivalence to reference bevacizumab, with cost advantages enhancing its suitability for retinal disease management. Transitioning to IBI305 can improve safety, efficacy, and cost-efficiency, establishing it as a preferred therapeutic option.